Helping solve the challenges of hospital initiation

Sotalol IV (sotalol hydrochloride injection 15 mg/mL for intravenous use) offers flexibility, control, and speed, so patients may avoid inconvenient hospitalization days.

Indication and usage.

Sotalol hydrochloride for intravenous use is an antiarrhythmic agent indicated for substitution for oral sotalol in patients who are unable to take sotalol orally.

  • Use for the maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation/flutter
  • Use for the treatment of documented life-threatening ventricular arrhythmias

See below for pediatric dosing guidance.

Recommended per Guidelines

The American Heart Association (AHA) recommends use of Sotalol IV in its Guidelines for Cardiopulmonary Resuscitation & Emergency Cardiovascular Care.1

Important Safety Information

WARNING: LIFE-THREATENING PROARRHYTHMIA See full prescribing information for complete boxed warning.
  • Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation
  • Do not initiate sotalol therapy if the baseline QTc is longer than 450 ms
  • If the QT interval prolongs to 500 ms or greater, the dose must be reduced, the duration of the infusion prolonged or the drug discontinued
  • Patient should be hospitalized in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring
  • Adjust the dosing interval based on creatinine clearance

The future of Sotalol IV: New FDA pathway for accelerated approval

AltaThera was recently selected by the FDA for a new regulatory program. This program allows for an accelerated pathway to develop new dosing for adult atrial fibrillation.

Pediatric dosing: patients <2 years of age

Sotalol IV dose should be reduced by a factor that depends on age.

News

  • IV Sotalol Donated for Veterinary Research on Boxer breed

    Chicago, IL – January 2019 – AltaThera has donated vials of IV sotalol to the Veterinary Program at the University of Pennsylvania to better understand heart arrhythmias in dogs.

    As stated by Professor Anna Gelzer, PhD, Doctor of Veterinary Medicine, “Boxers are at an increased risk of arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited disease of the heart muscle. We are interested to test [IV sotalol’s] ability to suppress arrhythmia inducibility during an electrophysiologic study.”

    AltaThera remains committed to research in all areas of cardiac arrhythmia and is excited about Dr. Gelzer’s clinical program.”

    Read More
  • New patent issued

    Chicago, IL – Dec. 24, 2019 – Today, AltaThera Pharmaceuticals, LLC, a hospital pharmaceutical company focused on commercializing acute-care hospital products, announced that the US Patent and Trademark Office has issued a  new patent covering methods of treatment for Sotalol IV. The patent is effective through August 2038.

    Read More
  • Gary Dickey named AltaThera Regional Sales Manager, East

     

    CHICAGO, IL – August 12, 2019 -Gary Dickey has joined AltaThera Pharmaceuticals as Regional Sales Manager, East Region.

    Gary joining the management team is an important step in AltaThera’s commercial efforts, as the company prepares to expand its field force to more effectively serve its hospital-based customers in cardiac electrophysiology.

    Gary, who has more than 20 years of experience in both the medical device and specialty pharmaceutical industry, joins AltaThera after successful leadership roles at Medtronic, AstraZeneca and Covidien. He has extensive experience in the field of electrophysiology which aligns with the company’s vision for the growth of Sotalol IV for treating cardiac arrhythmias.

    About AltaThera: AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on commercializing therapies for unmet medical needs of physicians, hospitals and their patients. AltaThera’s first commercial product is a critically valuable anti-arrhythmic in the hospital space.

    Read More
  • AltaThera Partners with Rush University Hospital to Support Arrhythmia Research in Vietnam

    Chicago, IL – 03/28/19  AltaThera Pharmaceuticals has recently partnered with Rush University Medical Center to support arrhythmia research around the world.  Through a charitable donation of the medication IV Sotalol (sotalol hydrochloride injection 15mg/mL for intravenous use), AltaThera is supporting important research regarding prophylaxis for post-op dysrhythmias.  The research is scheduled to take place at Hanoi Heart Hospital in Hanoi, Vietnam over the course of 2019/2020.

     Click here for Full IV Sotalol Prescribing Information, including Boxed Warning

    Read More
  • AltaThera selected by FDA to participate in a new regulatory program called Model-Informed Drug Development